CytomX Therapeutics Announces Board and Executive Changes
Ticker: CTMX · Form: 8-K · Filed: Mar 22, 2024 · CIK: 1501989
| Field | Detail |
|---|---|
| Company | Cytomx Therapeutics, INC. (CTMX) |
| Form Type | 8-K |
| Filed Date | Mar 22, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.00001, $120,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-compensation, board-of-directors
TL;DR
CytomX adds a director and adjusts exec pay; board shakeup incoming.
AI Summary
CytomX Therapeutics, Inc. announced on March 20, 2024, changes in its board of directors and executive compensation. Specifically, Dr. Steven D. Agger was appointed as a new director, and the company also filed amendments to its bylaws and reported on compensatory arrangements for its officers.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — The filing primarily concerns routine corporate governance changes and executive appointments, not significant financial events or operational disruptions.
Key Players & Entities
- CytomX Therapeutics, Inc. (company) — Registrant
- Dr. Steven D. Agger (person) — Newly appointed director
- March 20, 2024 (date) — Date of earliest event reported
FAQ
Who was appointed as a new director to CytomX Therapeutics, Inc.'s board?
Dr. Steven D. Agger was appointed as a new director.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is March 20, 2024.
What are the main items reported in this 8-K filing?
The filing reports on the departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements of certain officers, and amendments to articles of incorporation or bylaws.
In which state was CytomX Therapeutics, Inc. incorporated?
CytomX Therapeutics, Inc. was incorporated in Delaware.
What is the principal business address of CytomX Therapeutics, Inc.?
The principal business address is 151 Oyster Point Blvd, Suite 400, South San Francisco, California, 94080.
Filing Stats: 845 words · 3 min read · ~3 pages · Grade level 10.7 · Accepted 2024-03-22 16:06:56
Key Financial Figures
- $0.00001 — nge on which registered Common Stock, $0.00001 par value per share CTMX Nasdaq Glo
- $120,000 — participant involving amounts exceeding $120,000 and in which Dr. Su had or will have a
Filing Documents
- d803852d8k.htm (8-K) — 29KB
- d803852dex31.htm (EX-3.1) — 130KB
- 0001193125-24-075211.txt ( ) — 317KB
- ctmx-20240320.xsd (EX-101.SCH) — 3KB
- ctmx-20240320_lab.xml (EX-101.LAB) — 18KB
- ctmx-20240320_pre.xml (EX-101.PRE) — 11KB
- d803852d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 3.1 Amended and Restated Bylaws of CytomX Therapeutics, Inc., effective March 20, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CYTOMX THERAPEUTICS, INC. Date: March 22, 2024 By: /s/ Lloyd Rowland Lloyd Rowland SVP, General Counsel